☆ 4.6 Article

MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway

Hui Ma et al.

Summary: This study reveals that persistent DNA damage caused by a defective BRCA pathway induces tumor immunosuppression and T-lymphocyte infiltration in HCC through the cGAS-STING pathway, providing insight into tumor immune microenvironment remodeling that may help improve HCC response to PD-1 antibody treatment.

HEPATOLOGY (2023)

Add to Collection

Letter Oncology

Frontline treatment approaches in TP53-aberrant mantle cell lymphoma

Nikesh N. Shah et al.

LEUKEMIA & LYMPHOMA (2023)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

EBV-Mir-BART5-5p targets p53 independent pathway in cytoplasm: Potential role in EBV lymphomagenesis

Wei-Ting Wang et al.

GENES & DISEASES (2023)

Add to Collection

Article Oncology

Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells

Zhe Sun et al.

Summary: Inhibition of CTP synthase selectively decreases cell viability and induces DNA replication stress in MYC-overexpressing cells. Combined inhibition of CTP synthase and ATR is synthetically lethal in MYC-overexpressing cells, leading to cell death in vitro and decreased tumor growth in vivo. Interfering with CTPS1 but not CTPS2 is necessary to induce replication stress and cell death in MYC-deregulated cancer cells in the presence of an ATR inhibitor.

CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter Open-Label, Single-Arm, Phase II Trial

Eva Gine et al.

Summary: The study investigated the effectiveness of tailored treatment with ibrutinib in combination with rituximab (IR) in MCL patients, indicating significant responses in indolent clinical forms of MCL. The frontline IR combination achieved a high rate of complete responses and undetectable minimal residual disease in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1

Yuxiang Lin et al.

Summary: CTPS1 is upregulated in TNBC and is associated with poor prognosis in patients. Silencing CTPS1 inhibits TNBC cell proliferation, migration, and invasion. YBX1 can bind to the promoter of CTPS1 and promote its transcription. Furthermore, YBX1 expression is positively correlated with CTPS1 in TNBC tissues.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Add to Collection

Review Biology

Cancer metabolism and tumor microenvironment: fostering each other?

Yiyuan Yuan et al.

Summary: Metabolic reprogramming in cancer cells not only supports rapid proliferation but also helps cells survive under genetic or environmental stress, closely associated with genetic changes. The concept of metabolite signaling sheds light on the important role of metabolites in cancer growth and progression.

SCIENCE CHINA-LIFE SCIENCES (2022)

Add to Collection

Article Hematology

Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments

Preetesh Jain et al.

Summary: The field of mantle cell lymphoma (MCL) has made remarkable progress in molecular pathogenesis, prognostication, and newer treatments. MCL consists of various clinical subtypes and has complex pathogenesis. Treatment options range from conventional chemotherapy to targeted therapy and cellular therapy.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Editorial Material Oncology

A Novel Synthetic Lethal Approach to Target MYC-Driven Cancers

Roman M. Chabanon et al.

CANCER RESEARCH (2022)

Add to Collection

Article Oncology

De novo pyrimidine synthesis fuels glycolysis and confers chemoresistance in gastric cancer

Daochuan He et al.

Summary: This study investigates the impact of de novo pyrimidine synthesis on aerobic glycolysis in cancer cells, and demonstrates that it can enhance Notch signaling and up-regulate critical glycolytic enzymes. Furthermore, the study shows that up-regulation of key enzymes for pyrimidine synthesis confers chemotherapeutic resistance in gastric cancer, while inhibition of the pyrimidine biosynthetic pathway increases sensitivity to chemotherapy in cancer cells.

CANCER LETTERS (2022)

Add to Collection

Review Oncology

Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical Perspectives

Zhuoya Yu et al.

Summary: Metabolic reprogramming, a hallmark of cancer progression, supports tumorigenesis and tumor progression by allowing cells to uptake essential nutrients and altering metabolic pathways to meet increased demands for energy and biosynthetic precursors. Activated oncogenes coordinate with altered metabolism to control cell-autonomous pathways, potentially leading to tumorigenesis. Targeting metabolic features of hematologic malignancies has shown promising therapeutic potential in both clinical and preclinical studies.

CANCER RESEARCH (2022)

Add to Collection

Article Cell Biology

CTPS1 suppresses proliferation and migration in colorectal cancer cells

Fahong Wu et al.

Summary: In this study, we identified CTPS1 as an important diagnostic biomarker for colorectal cancer. We found that CTPS1 promotes tumor proliferation and metastasis and regulates CRC progression through cell cycle and p53 pathways.

CELL CYCLE (2022)

Add to Collection

Review Medicine, General & Internal

Mantle-Cell Lymphoma

James O. Armitage et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma

Diana D. Shi et al.

Summary: This study found that IDH1-mutant glioma cells are hypersensitive to drugs targeting enzymes in the de novo pyrimidine nucleotide synthesis pathway. They also showed that a brain-penetrant DHODH inhibitor exhibits monotherapy efficacy against IDH-mutant gliomas, based on experiments using a genetically engineered mouse model and patient-derived models.

CANCER CELL (2022)

Add to Collection

Review Oncology

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?

Amer Beitinjaneh et al.

Summary: Autologous hematopoietic cell transplant (auto-HCT) has been the standard care for younger and physically fit mantle cell lymphoma (MCL) patients after chemoimmunotherapy (CIT) induction. Bruton's tyrosine kinase (BTK) inhibitors have shown good outcomes as salvage therapies, but their long-term efficacy remains uncertain, especially in high-risk MCL cases. Allogeneic HCT (allo-HCT) has been the primary option for long-term remission and possible cure in MCL relapse and some upfront consolidation cases. The recent approval of chimeric antigen receptor T (CAR-T) cell therapy for relapsed and refractory (R/R) MCL has brought about a paradigm shift, with preliminary evidence suggesting that CAR-T therapy may overcome known biological risk factors in MCL. The role of CAR-T therapy among other approved therapies and HCT needs to be further defined. Based on current evidence, auto-HCT remains the standard frontline consolidation therapy, while CAR-T therapy is preferred for R/R MCL patients, especially those who failed BTK inhibitors. In certain high-risk MCL cases, CAR-T cell therapy may be considered prior to BTK inhibitors, preferably as part of a clinical trial. The role of allo-HCT in the CAR-T era remains unclear but remains a viable option for eligible patients who have no access or have failed CAR-T therapy.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation

Mengjie Hu et al.

Summary: Inhibition of ATM can enhance immune checkpoint blockade therapy by promoting cytoplasmic leakage of mitochondrial DNA and activating the cGAS/STING pathway, delaying tumor growth, enhancing the efficacy of anti-PD-1 therapy, and increasing lymphocyte infiltration into the tumor microenvironment. Additionally, ATM mutations, especially nonsense mutations, can predict clinical benefits of ICB therapy.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Microbiology

Epstein-Barr Virus Induced Cytidine Metabolism Roles in Transformed B-Cell Growth and Survival

Jin Hua Liang et al.

Summary: EBV infection is associated with various cancers, with CTPS1 and CTPS2 potentially playing important roles in EBV-infected B cells. Lack of CTPS1 can impact EBV DNA synthesis, while deficiency of both CTPS1 and CTPS2 leads to stronger phenotypes, suggesting CTPS1/2 as potential therapeutic targets for EBV-driven lymphoproliferative disorders.

MBIO (2021)

Add to Collection

Review Oncology

The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer

John Kwon et al.

CANCER DISCOVERY (2020)

Add to Collection

Review Endocrinology & Metabolism

A non-proliferative role of pyrimidine metabolism in cancer

Aarif Siddiqui et al.

MOLECULAR METABOLISM (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy

Jiaqi Li et al.

MOLECULES (2020)

Add to Collection

Article Medicine, Research & Experimental

Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation

Emmanuel Martin et al.

JCI INSIGHT (2020)

Add to Collection

Article Oncology

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Triparna Sen et al.

CANCER DISCOVERY (2019)

Add to Collection

Article Cell Biology

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma

Liang Zhang et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Add to Collection

Article Cell Biology

Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells

Xiuxing Wang et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Add to Collection

Review Immunology

The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer

Tuo Li et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Understanding the Intersections between Metabolism and Cancer Biology

Matthew G. Vander Heiden et al.

CELL (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression

Zhaoyong Li et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2016)

Add to Collection

Review Cell Biology

The Emerging Hallmarks of Cancer Metabolism

Natalya N. Pavlova et al.

CELL METABOLISM (2016)

Add to Collection

Article Oncology

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

C. Y. Cheah et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Multidisciplinary Sciences

CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation

Emmanuel Martin et al.

NATURE (2014)

Add to Collection

Article Medicine, General & Internal

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael L. Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Oncology

Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer

Wen Lee Tan et al.

CANCER BIOLOGY & THERAPY (2011)

Add to Collection

Article Biochemical Research Methods

Structure of the synthetase domain of human CTP synthetase, a target for anticancer therapy

Petri Kursula et al.

ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.